Patient Profiles and Outcomes in Endometriosis with Malignant or Borderline Ovarian Tumors: Insights from an ESGO Designated Center of Excellence
By
Maximilian Heinz Beck
Paul Kordowitzki
Eva Roser
Anna Trelinska-Finger
Emily Schoof
Lukas Chinczewski
Sylvia Mechsner
Jalid Sehouli
April 16, 2026
Clinical Scorecard: Patient Profiles and Outcomes in Endometriosis with Malignant or Borderline Ovarian Tumors: Insights from an ESGO Designated Center of Excellence
At a Glance
Category Detail
Condition Endometriosis with malignant or borderline ovarian tumors Key Mechanisms Estrogen overstimulation, ARID1A mutation, PI3K/AKT/mTOR pathway activation Target Population Women of reproductive age with endometriosis and ovarian tumors Care Setting Tertiary academic medical center
Key Highlights
Endometriosis affects 5-10% of women of reproductive age. Increased risk of ovarian cancer in women with deep infiltrating endometriosis. Atypical endometriosis is a premalignant precursor lesion. Endometriosis-associated ovarian cancer can show histopathologic transitions. Survival outcomes evaluated in patients with malignant or borderline ovarian tumors. Guideline-Based Recommendations
Diagnosis
Histologic confirmation of endometriosis during surgery for ovarian tumors. Management
Consideration of endometriosis status in treatment planning for ovarian tumors. Monitoring & Follow-up
Regular follow-up for disease recurrence in patients with endometriosis-associated tumors. Risks
Increased risk of ovarian cancer associated with endometriosis. Patient & Prescribing Data
Patients with malignant or borderline ovarian tumors and concurrent endometriosis.
Treatment strategies may vary based on endometriosis status and tumor characteristics.
Clinical Best Practices
Utilize a multidisciplinary approach for managing patients with endometriosis and ovarian tumors. Incorporate genetic counseling for patients with a family history of ovarian cancer. Related Resources & Content
